Exagen Inc.

Through groundbreaking technology, we are revolutionizing the landscape of autoimmune disease diagnostics at Exagen Inc. As a patient-focused and discovery-driven commercial-stage life sciences company, we are dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune conditions. Our relentless pursuit of laboratory excellence has enabled us to develop next-generation testing solutions that empower physicians with the objective information needed for accurate, timely differential diagnosis and optimized therapeutic intervention.

At the core of our innovation is our proprietary Cell-Bound Complement Activation Products (CB-CAPs) technology, which assesses the activation of the complement system—a biological pathway widely implicated in many autoimmune diseases, including Systemic Lupus Erythematosus (SLE). Our flagship AVISE® brand of testing products leverages this advanced technology to provide unparalleled insights, helping to distinguish between overlapping symptoms and guide patients on their journey to improved health. By integrating sophisticated diagnostic tools with a commitment to personalized medicine, we are reshaping how rheumatologists approach complex autoimmune and autoimmune-related diseases, ensuring that every patient receives the precise care they deserve.